samedan logo
 
 
spacer
home > pmps > autumn 2019 > regulation, regulation, regulation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Regulation, Regulation, Regulation





The EU Medical Device Regulation (MDR) and the EU In Vitro Device Regulation (IVDR) introduce substantial changes that impact all manufacturers of medical devices. However, these regulations also have implications for pharmaceutical companies producing drug device combination products or companion diagnostics. Understanding the new requirements and implementing them is of the utmost urgency as the deadlines for compliance are approaching fast (May 2020 and May 2022 respectively), and products containing non-compliant devices after these deadlines will have to be withdrawn from the market.

The new device regulations are complex and are causing unprecedented upheaval in the industry. The further difficulty for pharma businesses is the lack of familiarity with the MDR and the fact that they may have to liaise with a notified body for the first time.

 

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Elizma Parry brings over 25 years of experience to the Maetrics team and provides clients with expert counsel in the clinical practice environment. As a highly qualified industry professional, Elizma is a proven leader with a strong track record of clinical safety, regulatory, and quality management experience. Having recently been in a shared acting role as the head of a Europe-based notified body before joining Maetrics, she was also managing a multi-national clinical team within the notified body that was responsible for the clinical safety, performance, and clinical benefit conformity assessments of medical device manufacturers’ clinical evidence, as well as the lead for liaising with the Medicines and Healthcare products Regulatory Agency. Elizma has also worked across quality, regulatory, and biotechnology environments throughout her career. She has developed and presented training courses across the UK and US, including joint development of a bespoke Cranfield University course for notified body clinical assessors.


Print this page
Send to a friend
Privacy statement
News and Press Releases

X-Chem Acquires ComInnex

WALTHAM, Mass.; Oct. 25, 2021 (Business Wire) – X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement